Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[LAK cell adoptive immunotherapy and its problems].

Y Yamaguchi1, T Takayama, H Kawami

  • 1Department of Surgery, Hiroshima University, Japan.

Nihon Geka Gakkai Zasshi
|September 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).

ESMO open·2021
Same author

Influence of lingual plate fracture pattern on remodelling site during the healing process of sagittal split ramus osteotomy.

International journal of oral and maxillofacial surgery·2021
Same author

Shift-and-add image processing incorporated with the unsharp masking method.

Applied optics·2021
Same author

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial.

The British journal of dermatology·2021
Same author

Effects of molecular crowding environment on the acquisition of toxic properties of wild-type SOD1.

Biochimica et biophysica acta. General subjects·2019
Same journal

[MODIFIED BLUMGART SUTURING TECHNIQUE (NAGOYA METHOD) IN PANCREATICOJEJUNOSTOMY].

Nihon Geka Gakkai zasshi·2018
Same journal

[MODIFIED BLUMGART TECHNIQUE OF PANCREATOJEJUNOSTOMY（BLUMGART―DUMPLING METHOD)].

Nihon Geka Gakkai zasshi·2018
Same journal

[BLUMGART’S TYPE ANASTOMOSES;AN EMERGING TECHNIQUE FOR PANCREATICODUODENECTOMY].

Nihon Geka Gakkai zasshi·2018
Same journal

[WHAT WE CAN LEARN FROM A CASE OF MEDICAL MALPRACTICE―MEDICAL NEGLIGENCE CASE DISMISSED FOR INITIAL DIAGNOSIS OF BENIGN COLONIC POLYPS (THAT LATER TURNED CANCEROUS)].

Nihon Geka Gakkai zasshi·2018
Same journal

[WOUND CLOSURE METHODS FOR PREVENTION OF SURGICAL SITE INFECTION AND PATHOLOGIC SCARS－INCISION AND SUTURE METHODS FOR PREVENTION OF SSI, HYPERTROPHIC SCARS AND KELOID-].

Nihon Geka Gakkai zasshi·2018
Same journal

[PREFACE TO “WOUND CLOSURE METHODS FOR PREVENTION OF SURGICAL SITE INFECTION AND PATHOLOGIC SCARS ― INCISION AND SUTURE METHODS FOR PREVENTION OF SSI, HYPERTROPHIC SCARS AND KELOID ―”].

Nihon Geka Gakkai zasshi·2018
See all related articles

Adoptive immunotherapy (AIT) using lymphokine-activated killer (LAK) cells showed partial response in advanced cancer patients. Further AIT strategies are needed to improve LAK cell tumor targeting for better gastrointestinal cancer treatment.

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Therapy

Context:

  • Advanced cancer presents significant treatment challenges.
  • Adoptive immunotherapy (AIT) using lymphokine-activated killer (LAK) cells is an emerging therapeutic strategy.
  • Combination therapies are being explored to enhance treatment efficacy.

Purpose:

  • To investigate the clinical efficacy of LAK cell AIT combined with plasma exchange and interleukin-2 (IL-2) in advanced cancer patients.
  • To design and evaluate a novel AIT protocol targeting liver and lung tumors.
  • To explore strategies for improving LAK cell tumor accumulation and recognition.

Summary:

  • The initial study involved 24 advanced cancer patients treated with LAK cell AIT, plasma exchange, and IL-2, resulting in a 20% partial response (PR) rate.

Related Experiment Videos

  • A subsequent AIT protocol incorporating plasma exchange, OK-432, IL-2, and cyclophosphamide was administered to 10 patients targeting liver and lung tumors, achieving a 10% PR rate in metastatic liver cancer.
  • The findings suggest a need for enhanced LAK cell delivery and tumor targeting to improve outcomes, particularly for gastrointestinal cancers.

    • Impact:

    • The study provides preliminary data on the efficacy of LAK cell AIT in advanced cancers.
    • It highlights the potential of combination immunotherapy and targeted drug delivery.
    • Further research is warranted to optimize AIT strategies for improved cancer treatment, especially for gastrointestinal malignancies.